Aurobindo Pharma is currently trading at Rs. 573.30, up by 73.10 points or 14.61% from its previous closing of Rs. 500.20 on the BSE.
The scrip opened at Rs. 550.20 and has touched a high and low of Rs. 594.00 and Rs. 550.20 respectively. So far 221015 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 838.00 on 30-Apr-2019 and a 52 week low of Rs. 389.70 on 14-Nov-2019.
Last one week high and low of the scrip stood at Rs. 594.00 and Rs. 482.50 respectively. The current market cap of the company is Rs. 29308.65 crore.
The promoters holding in the company stood at 51.87%, while Institutions and Non-Institutions held 34.60% and 13.53% respectively.
Aurobindo Pharma has received the Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAI) status from the US Food and Drug Administration (USFDA) for its Unit IV, a general injectable formulation manufacturing facility situated at Pashamylaram, Hyderabad. The USFDA had inspected company's Unit IV from November 4, 2019 to November 13, 2019.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
